Three-Tesla Magnetic Resonance–Guided Prostate Biopsy in Men With Increased Prostate-Specific Antigen and Repeated, Negative, Random, Systematic, Transrectal Ultrasound Biopsies: Detection of Clinically Significant Prostate Cancers

Hoeks, Caroline; Schouten, Martijn; Bomers, Joyce G. R.; Hoogendoorn, Stefan P.; Kaa, Christina A. Hulsbergen‐van de; Hambrock, Thomas; Vergunst, H.; Sedelaar, J.P. Michiel; Fütterer, Jurgen J.; Barentsz, Jelle O.

doi:10.1016/j.eururo.2012.01.047

Cited by 208 publications

(129 citation statements)

References 29 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Hence, the detection rate for clinically significant cancer in our study is 100 %. This is in accordance with and even higher than observed in the review of the literature [12,14,15,18,19,29]. This emphasizes the capability of MRGB to diagnose clinically significant cancer in patients after negative TRUS.…”

supporting

confidence: 90%

See 1 more Smart Citation

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Polanec

Helbich

Margreiter

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

!Objectives: To evaluate the detection rate of prostate cancer (PCa) after magnetic resonance-guided biopsy (MRGB); to monitor the patient cohort with negative MRGB results and to compare our own results with other reports in the current literature. Materials and Methods: A group of 41 patients was included in this IRB-approved study and subjected to combined MRI and MRGB. MRGB was performed in a closed 1.5 T MR unit and the needle was inserted rectally. The follow-up period ranged between 12 and 62 months (mean 3.1 years). To compare the results with the literature, a systematic literature search was performed. Eighteen publications were evaluated. Results: The cancer-suspicious regions were punctured successfully in all cases. PCa was detected in eleven patients (26.9 %) who were all clinically significant. MRGB showed a benign histology in the remaining 30 patients. In the followup (mean 3.1 years) of patients with benign histology, no new PCa was diagnosed. The missed cancer rate during follow-up was 0.0 % in our study. Conclusion: MRGB is effective for the detection of clinically significant cancer, and this is in accordance with the recent literature. In the follow-up of patients with benign histology, no new PCa was discovered. Although the probability of developing PCa after negative MRGB is very low, active surveillance is reasonable.

show abstract

supporting

confidence: 90%

“…Lane and collaborators reported that cancer was detected in 24 % of patients during repeated TRUS for persistent clinical signs of PCa [33]. The rate of missed cancer in MRGB studies is reported at 6 % in a paper published by Hoeks et al, with a mean follow-up of only five months [15]. These data are comparable to the results of Engehausen et al [14].…”

mentioning

confidence: 60%

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Polanec

Helbich

Margreiter

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

“…Bu yöntem fazla zaman alması nedeniyle sistemik biyopsi yapılması için uygun bir yöntem olmadığı belirtilmektedir. Sistematik prostat biyopsi yapılmadığı için önemsiz prostat kanseri daha az sıklıkla tespit edildiği bildirilmiştir (36). Ayrıca birçok önemli kanser hedeflenen prostat dokusunun dışında geliştiğinden MR ile hedef biyopsi yapıldığında bazı kanserlerin atlanmış olabileceği endişesine yol açabileceği ifade edilmektedir (35).…”

Section: Multiparametrik Manyetik Rezonans Görüntüleme (Mp-mri)unclassified

Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”

Özden¹,

Mercimek²

2015

uob

View full text Add to dashboard Cite

“…Using in-bore MRI guided biopsy (MRGB) real-time MR imaging is performed to guide the biopsy procedure. A recent systematic review demonstrated increased TDR of significant prostate cancer in a large cohort using MRGB [17,22,27]. Despite these results MRGB remains controversial due to impracticalities, as its low availability, required expertise and time consuming nature.…”

Section: Introductionmentioning

confidence: 99%

“…The mpMRI information is used 'cognitively' by the physician to target tumour suspicious areas of the prostate using TRUS without applying image fusion [39,40]. All these techniques demonstrate an increased TDR of significant prostate cancer compared to systematic TRUS biopsy [17,[25][26][27][28][29][30][31][32][33][34][35][36][39][40][41][42]. There is no consensus which technique for targeted biopsy should be preferred.…”

Section: Introductionmentioning

confidence: 99%

Fusion Target Biopsy of the Prostate Using Real-Time Ultrasound and MR Images. A Multicenter RCT on Target Biopsy Techniques in the Diagnosis of Prostate Cancer

Wegelin¹,

Melick²

2015

J Clin Trials

View full text Add to dashboard Cite

Background: The current standard technique for prostate cancer detection is trans-rectal ultrasound (TRUS) guided biopsy, and is renowned for its low sensitivity. Developments of multiparametric MRI techniques have increased the detection of significant prostate cancer. Currently there are three techniques utilizing MRI for targeted biopsy: MRI-TRUS fusion, 'cognitive' TRUS, and in-bore MRI guided biopsy. There is no consensus which should be preferred. The current study aims to compare prostate cancer detection rates of three target biopsy procedures.

show abstract

Three-Tesla Magnetic Resonance–Guided Prostate Biopsy in Men With Increased Prostate-Specific Antigen and Repeated, Negative, Random, Systematic, Transrectal Ultrasound Biopsies: Detection of Clinically Significant Prostate Cancers

Cited by 208 publications

References 29 publications

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review

Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”

Fusion Target Biopsy of the Prostate Using Real-Time Ultrasound and MR Images. A Multicenter RCT on Target Biopsy Techniques in the Diagnosis of Prostate Cancer

Contact Info

Product

Resources

About